Year | Ceftriaxone | Azithromycin | Cefixime | Ciprofloxacin | Spectinomycin | Gentamicin | Ī²-lactamase |
---|
2006 | 87.6ā100 | 95.3ā100 | ā | 49.5ā99.1 | ā | ā | 96.3ā100 |
2007 | 95.3ā100 | 75.6ā100 | ā | 90.3ā100 | ā | ā | 100 |
2008 | 93.8ā100 | 41.7ā100 | ā | 94.2ā100 | 100 | ā | 98ā100 |
2009 | 95.8ā100 | 87ā100 | 100 | 92.9ā100 | 100 | 100 | 97.5ā100 |
2010 | 93.8ā100 | 89.1ā100 | 97.1ā100 | 92.6ā100 | 100 | 100 | 98.2ā100 |
2012 | 95.8ā100 | 75a ā 100 | 95.8ā100 | 80b - 100 | 100 | 98.1ā100 | 97.9ā98.1 |
2013 | 95.4ā100 | 89a - 100 | 95.5ā100 | 80b - 100 | 100 | 97.3ā100 | 99.1ā100 |
- The table contains data from; Austria (2012ā2013, all antimicrobials); Belgium (2006ā2009, no gentamicin or cefixime data); Cyprus (2012ā2013, no spectinomycin, gentamicin or Ī²-lactamase data); Denmark (2006ā2009, ceftriaxone, ciprofloxacin and Ī²-lactamase data only); France (2008ā2010, no azithromycin or gentamicin data); Greece (2007ā2010, no gentamicin data); Iceland (2012ā2013, no spectinomycin, gentamicin or Ī²-lactamase data); Ireland (2012, ceftriaxone, azithromycin and cefixime data only); Italy (2007, azithromycin and ciprofloxacin only, 2010ā2011 all antimicrobials); Malta (2012ā2013, no gentamicin or Ī²-lactamase data); Norway (2012ā2013, no Ī²-lactamase data); Portugal (2009ā2010, no azithromycin data); Slovenia (2011ā2013, all antimicrobials); Spain (2006ā2009, no cefixime or gentamicin data); Sweden (2006ā2009, no cefixime or gentamicin data); The Netherlands (2006ā2010, ceftriaxone, ciprofloxacin and Ī²-lactamase data only) and the UK (2006ā2010, no gentamicin data). Data from Slovenia was only available for 2011 so data is not shown, however all concordances for 2011 were within specified limits
- aAll discrepant isolates on the resistance breakpoint
- bOnly a very low number of isolates available for comparison from two labs, so 1ā2 mismatches resulted in only 80% concordance, however overall concordance of the resistance category comparisons was ā„97%